GlobalData on MSN
Moderna scraps mRNA vaccine in congenital CMV on Phase III failure
While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...
Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women ...
Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...
Stocktwits on MSN
Moderna Stock Slides After-Hours On CMV Vaccine Failure In Phase 3 Trial — Retail Traders Warn Of ‘Endless’ Cash Burn
Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a ...
Investor's Business Daily on MSN
Moderna Topples, Threatening Its 50-Day Line, After A Key Vaccine Bites The Dust
Moderna stock toppled Thursday after the biotech company's experimental CMV vaccine failed in a Phase 3 study of 7,500 women.
Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital cytomegalovirus (CMV) infections – once ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results